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Colectomy averted: A successful case report of Fidaxomicin administration 
through a loop ileostomy for fulminant, Clostridioides difficile infection 
 
ABSTRACT 
Clostridioides difficile infection is considered an urgent public health threat by the Centers for 
Disease Control and Prevention. Recent practice guidelines recommend either vancomycin or 
fidaxomicin for an initial episode of Clostridioides difficile infection and further recommend a 
subtotal colectomy in severe cases. There is limited data discussing novel approaches for 
fidaxomicin administration in severe Clostridioides difficile infection to avert colectomy. We 
describe an off-label route of fidaxomicin administration through a loop ileostomy twice daily 
with successful outcome. 
Key Words Clostridioides difficile, Clostridium difficile, Fidaxomicin, loop ileostomy, colonic lavage 
BACKGROUND 
Clostridioides difficile infection (CDI) is increasing in health-care settings and is associated with 
substantial morbidity and mortality. Mortality rates of 15-25% have been reported within 30 days 
of CDI diagnosis.1 Direct costs for acute care of CDI in the U.S. were estimated to be $4.8 
billion; and is likely substantially higher due to indirect cost management of the disease.1 
Fulminant disease is characterized by hypotension or shock, ileus, or megacolon based on the 
Infectious Disease Society of America (IDSA) 2018 clinical practice guidelines for CDI.2 
Pharmacologic treatment options for initial and recurrent episodes of CDI include vancomycin or 
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fidaxomicin rather than metronidazole.2 Oral fidaxomicin 200mg twice daily for ten days was 
approved by the FDA in 2011 for the treatment of Clostridioides difficile associated diarrhea. 
Fidaxomicin effectively reduced recurrence of CDI and neutralize species of CDI, yielding 
symptomatic cure by targeting ‘switch regions’ within bacterial RNA polymerases.3,4  
When treating fulminant CDI, the IDSA guidelines recommend oral vancomycin (500mg four 
times daily), intravenous metronidazole (500mg three times daily) and, if ileus is present, 
vancomycin may also be administered per rectum (500 mg in approximately 100 mL normal 
saline per rectum every six hours as a retention enema).2,5 If surgical management is necessary, a 
subtotal colectomy is recommended.2 However, complete removal of the large bowel has been 
associated with a 30-day mortality of 20- 71%.5 Performing a diverting loop ileostomy with 
colonic lavage, referred to as the ‘Pittsburgh Protocol,’ can be utilized as an alternative surgical 
option for fulminant disease.  This procedure is associated with decreased morbidity; defined as 
patients requiring fewer vasoactive agents or development of shock, in addition to a significant 
reduction in mortality.5 The Pittsburgh protocol includes colonic lavage with eight liters of 
polyethylene glycol intraoperatively after formation of loop ileostomy, proceeded by antegrade 
vancomycin flushes (500mg in 500mL Ringer’s lactate every eight hours) and intravenous 
metronidazole (500 mg every eight hours) for ten days.5,6  
We present a case of fulminant CDI surgically managed with loop ileostomy, administration of 
the Pittsburgh protocol and the addition of fidaxomicin ileostomy administration. Following the 
procedure, addition of antegrade fidaxomicin ileostomy administration demonstrated marked 
clinical improvement, avoidance of bowel resection and clinical cure with ileostomy reversal at 
thirty days. This case describes the off-label administration route of fidaxomicin, in conjunction 
with intravenous metronidazole and vancomycin bowel irrigation.  
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CASE REPORT 
A 75-year-old woman with a history of oxygen dependent COPD, hyperlipidemia, chronic 
kidney disease, hypertension and bipolar disorder presented to the emergency department for 
complaints of weakness, loss of appetite, diffuse abdominal pain and diarrhea 4-5 times a day, 
beginning five days prior to admission. The first incident of diarrhea was associated with a small 
amount of observed blood which had stopped spontaneously. Five days prior to admission, the 
patient completed a ten-day course of oral clindamycin for a foot infection. On admission she 
was afebrile and hemodynamically stable. Physical examination of the abdomen revealed diffuse 
rebound tenderness. Initial laboratory data revealed leukocytosis (17.8 x 109/L) and elevated 
serum creatinine 1.8 mg/dL (baseline 1.2mg/dL). A computed tomography (CT) of the abdomen 
and pelvis without contrast revealed diffuse colonic wall thickening from cecum to rectum with 
peri-colonic fat stranding consistent with colitis, and mild ascites.  
Initial pharmacotherapy for presumed CDI consisted of vancomycin (125mg orally every six 
hours) and metronidazole (500mg intravenously every eight hours). On day 2 of admission, stool 
PCR testing was positive for C. difficile and the medication regimen was modified to 
vancomycin (500mg orally every six hours) for three days and continuation of intravenous 
metronidazole for eighteen days. The patient refused rectal vancomycin administration. On day 
five of admission, despite receiving maximal pharmacologic support, the patient’s disease 
progressed, as evidenced by new onset hypotension (systolic blood pressure < 90 mmHg), 
worsening leukocytosis (30 x 109/L), the inability to tolerate enteral feeding and medication 
administration and subsequently was transferred to the medical/surgical intensive care unit. A 
repeat CT of the abdomen and pelvis without contrast revealed worsening, severe diffuse colitis, 
moderate ascites and new bowel wall edema. Due to the lack of clinical improvement, the patient 
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was brought to the operating room for laparotomy, loop ileostomy, placement of a Malecot® 
tube and a Jackson-Pratt drain with antegrade lavage of the colon utilizing the University of 
Pittsburgh protocol 6 (Appendix 1).  
Post-operative day one, fidaxomicin (200mg crushed tablet mixed in 100ml 0.9% normal saline 
twice daily) was added to the University of Pittsburgh protocol and administered through the 
loop ileostomy. After five days of fidaxomicin ileostomy therapy, the medication was 
discontinued and within twenty-four hours the patient’s condition began to deteriorate, noted by 
complaints of diffuse abdominal pain and an abdominal X-ray revealing a small bowel 
obstruction. (Figure 1.) Fidaxomicin ileostomy therapy was reinitiated in conjunction with the 
Pittsburgh protocol and continued for a total of fourteen days while the patient’s clinical status 
improved markedly; averting the need for a total colectomy. The patient returned to the hospital 
after thirty days from discharge for reversal of the ileostomy without complication or recurrence. 
Stability data available regarding crushed alternative routes of administration of fidaxomicin are 
limited. Currently, one study demonstrated two-hour stability while ensuring adequate 
bioavailability when dispersed into water and the other study utilized 0.9% normal saline as the 
diluent solution.7,8 
DISCUSSION 
This case demonstrates the successful use of fidaxomicin administration via diverting ileostomy.  
Our patient failed to improve adequately following the standard Pittsburgh protocol, oral 
vancomycin and intravenous metronidazole.  However, with the addition of fidaxomicin 
ileostomy administration, our patient responded.  Of interest, when fidaxomicin was 
discontinued after five days of administration, our patient’s clinical condition worsened.  Upon 
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reinitiation of fidaxomicin, she again improved, substantiating fidaxomicin efficacy on 
rechallenge.    
Only two other published cases describe the use of fidaxomicin administered by an alternative 
route. Once case describes a subtotal colectomy in a patient with recurrent CDI.7 Separately, a 
similar case to our report, denotes successful treatment of a patient with fulminant CDI where 
fidaxomicin was administered via mucous fistula.3 In this case, the patient underwent a partial 
colectomy where an external mucous fistula was created after failing to respond to oral and rectal 
vancomycin and intravenous metronidazole. Post-operatively pseudomembranes developed on 
the mucous fistula, prompting the addition of crushed fidaxomicin. The authors reported 
reduction in clinical burden of pseudomembranous disease after ten days of treatment with 
fidaxomicin.  Unlike our case, this administration was in a mucous fistula with visible 
pseudomembranes.  
While the 2018 IDSA guidelines recommend subtotal colectomy in severe CDI,2 newer surgical 
literature support colon-sparing ileostomy intervention to decrease morbidity and mortality. 
Unfortunately, retrospective cohort studies indicate that failure in these severe cases remains 
high (19%).6 Although the addition of fidaxomicin ileostomy administration was effective in this 
patient, a single case report is inadequate to make recommendations for use in patients.  
Additional studies to determine the safety and efficacy of fidaxomicin via ileostomy should be 
conducted before this can be recommended treatment in refractory CDI. 
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CONCLUSION 
Addition of antegrade administration of fidaxomicin via loop ileostomy in patients who are 
failing standard therapy may be an option that warrants further investigation in the treatment of 
fulminant Clostridioides difficile infection (CDI).   
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